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Abstract Transmembrane domains (TMDs) engage in protein-protein interactions that regulate
many cellular processes, but the rules governing the specificity of these interactions are poorly
understood. To discover these principles, we analyzed 26-residue model transmembrane proteins
consisting exclusively of leucine and isoleucine (called LIL traptamers) that specifically activate the
erythropoietin receptor (EPOR) in mouse cells to confer growth factor independence. We
discovered that the placement of a single side chain methyl group at specific positions in a
traptamer determined whether it associated productively with the TMD of the human EPOR, the
mouse EPOR, or both receptors. Association of the traptamers with the EPOR induced EPOR
oligomerization in an orientation that stimulated receptor activity. These results highlight the high
intrinsic specificity of TMD interactions, demonstrate that a single methyl group can dictate
specificity, and define the minimal chemical difference that can modulate the specificity of TMD
interactions and the activity of transmembrane proteins.
DOI: https://doi.org/10.7554/eLife.27701.001
Introduction
Specific interactions between proteins underlie much of biology. Proteomics analysis has identified
thousands of protein-protein interactions (e.g., [Bork et al., 2004]), but in most cases the molecular
basis for the ability of a protein to bind to specific protein partners but not to closely related pro-
teins is poorly understood. Integral membrane proteins constitute ~30% of the proteome of eukary-
otic cells and serve many important biological functions (Lehnert et al., 2004). Transmembrane (TM)
proteins contain TM domains (TMDs) that span the lipid bilayer. In multi-pass TM proteins, which
span the membrane multiple times, TMDs interact to properly fold the protein into a functional state
within the bilayer. For single-pass TM proteins, TMDs have traditionally been viewed as primarily
serving to anchor the protein into the lipid bilayer, but they can engage in highly specific intermolec-
ular protein-protein interactions that regulate protein oligomerization and activity (Langosch and
Arkin, 2009; Moore et al., 2008). TMDs can align laterally in the membrane and oligomerize via
hydrogen bonds, salt-bridges, or van der Waals packing interactions (Langosch and Arkin, 2009;
Moore et al., 2008; Bugge et al., 2016; Choma et al., 2000; Zhou et al., 2000). However, the anal-
ysis of TMD complexes has been hindered by the difficulties in obtaining high-resolution structures
of protein segments that cross membranes (Bugge et al., 2016).
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Despite these limitations, TMDs also present advantages to the study of protein-protein interac-
tions because they are short and usually adopt simple, helical structures in the membrane, which
may fold independently of linked globular domains. The functional relevance of a free-standing TMD
is illustrated by the E5 oncoprotein of bovine papillomavirus (BPV), a homodimeric, single-pass 44-
residue TM protein that binds specifically to the TMD of the platelet-derived growth factor b recep-
tor (PDGFbR), resulting in sustained receptor activation and cell transformation (Lai et al., 1998;
Petti et al., 1991; Schlegel et al., 1986; Goldstein et al., 1992; Petti and DiMaio, 1992; Talbert-
Slagle and DiMaio, 2009).
To study the interactions between TMDs, we developed a genetic system to isolate small (<50
residues), biologically active artificial TM proteins named traptamers (Freeman-Cook and DiMaio,
2005). In this approach, we construct libraries expressing many different traptamers with random-
ized hydrophobic segments, and use genetic selection to isolate rare clones with a desired biological
activity in mammalian cells. We have isolated traptamers that activate the PDGFbR and cause mor-
phologic transformation of fibroblasts; others that down-regulate expression of the HIV co-receptor,
CCR5, and confer resistance to R5-tropic strains of HIV; and still others that activate the human
erythropoietin receptor (hEPOR) and induce cell proliferation and erythroid differentiation of
hematopoietic progenitor cells (Cammett et al., 2010; Chaco´n et al., 2014; Freeman-Cook et al.,
2004, 2005; Scheideman et al., 2012).
The EPOR is a single-pass TM protein that exists in a monomer-dimer equilibrium in unstimulated
cells and is driven toward a productive dimeric form by EPO binding (Constantinescu et al., 2001;
Ebie and Fleming, 2007; Kubatzky et al., 2001; Livnah et al., 1999; Moraga et al., 2015;
Ruan et al., 2004). Ligand-induced dimerization of the EPOR in the proper orientation results in
autophosphorylation of constitutively bound JAK2 kinases, phosphorylation of the intracellular
domain of the EPOR, and initiation of intracellular signaling cascades (Seubert et al., 2003;
Syed et al., 1998; Witthuhn et al., 1993; Remy et al., 1999; Watowich, 2011). The mouse EPOR
(mEPOR) but not the hEPOR is also activated by gp55-P, a 55 kDa viral TM protein with a large, gly-
cosylated extracellular domain (Li et al., 1990). Point mutations in the TMDs of gp55-P and the
mEPOR can prevent EPOR activation (Amanuma et al., 1989; Chung et al., 1989; Zon et al., 1992;
Constantinescu et al., 1999). However, no gp55-P mutants displayed altered specificity, so the fea-
tures of gp55-P that allow it to distinguish between the closely related mEPOR and hEPOR are
unknown, and the role of extra-membrane segments of gp55-P has not been explored.
We reasoned that by shortening and drastically reducing the chemical complexity of traptamers
as model TM proteins, we could determine the minimal chemical complexity required to construct a
biologically active protein. Remarkably, we discovered that 26-residue traptamers consisting of only
leucines and isoleucines following an initiating methionine (LIL traptamers) can specifically activate
the PDGFbR and transform cells (Heim et al., 2015). Because these proteins are comprised exclu-
sively of two hydrophobic amino acids that differ chemically only by the placement of a single side
chain methyl group and cannot undergo post-translational modification, these results defined the
minimal chemical complexity required to generate an active protein.
Here, we report the isolation and characterization of similar LIL traptamers that activate the
mEPOR, the hEPOR, or both receptors. The active traptamers associated with the TMD of the target
EPOR and induced EPOR oligomerization in an orientation that supported signaling. Most strikingly,
the placement of a single methyl group at precise positions in the traptamer dictated its differential
ability to associate with and activate the hEPOR or the mEPOR. These results reveal principles that
govern the formation of an important class of protein-protein interactions by defining the minimal
chemical difference that can determine specificity.
Results
Isolation of LIL traptamers that cooperate with the erythropoietin
receptor
To isolate LIL traptamers that activate the EPOR, we screened the UDv6 traptamer library for pro-
teins that support interleukin-3 (IL-3)-independent proliferation of BaF3 cells engineered to express
the HA-tagged hEPOR (BaF3/hEPOR cells) (Figure 1A). Murine BaF3 cells are dependent on IL-3 for
survival and proliferation, and traptamers that activate the EPOR allow BaF3/hEPOR cells to
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proliferate in the absence of IL-3 (Cammett et al., 2010; Li et al., 1990). The UDv6 library expresses
LIL traptamers in which a methionine initiation codon is followed by 25 codons encoding equimolar
leucine and isoleucine in a random order (Heim et al., 2015). The vast majority of LIL traptamers in
UDv6 did not confer IL-3 independence.
Individual LIL traptamers were cloned from IL-3 independent cells and tested for their ability to
confer IL-3 independence in BaF3 cells lacking hEPOR expression, in BaF3/hEPOR cells, and in BaF3
cells expressing HA-tagged mouse EPOR (BaF3/mEPOR). Cells were infected with retroviruses
expressing a traptamer or with control MSCVp retrovirus vector, selected with puromycin, and incu-
bated in IL-3-free media. Five LIL traptamers stimulated IL-3-independent growth of BaF3/hEPOR
cells but not parental BaF3 cells (Figure 2A), demonstrating that the EPOR was required for the
activity of these traptamers. Although traptamers LH1, LH2, LH3, and LH4 cooperated with the
hEPOR, they did not cooperate with the mEPOR, highlighting the high specificity of these trap-
tamers. In contrast, LH5 cooperated with both the mEPOR and the hEPOR. The sequences of these
traptamers (shown in Figure 1B) are unrelated to the more complex sequences of the 44-residue
Figure 1. Isolation of traptamers that activate EPOR. (A) Scheme to isolate traptamers that activate the hEPOR. BaF3/hEPOR cells were infected with a
retrovirus library expressing LIL traptamers and selected in medium containing a reduced level of IL-3. Genes encoding traptamers were recovered
from genomic DNA isolated from live cells, cloned, re-introduced into naı¨ve BaF3/hEPOR cells and subjected to an additional round of selection in the
absence of IL-3. (Red bars, traptamers that activate hEPOR; grey bars, traptamers that do not activate hEPOR.) (B) Sequences of traptamers that confer
IL-3 independence in BaF3/hEPOR cells but not in parental BaF3 cells. M, methionine; L, leucine; I, isoleucine (colored red). Residues in boxes are
distinctive for LH5. Numbers at bottom indicate the position in the traptamer sequence.
DOI: https://doi.org/10.7554/eLife.27701.002
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Figure 2. Specificity of traptamer action. (A) BaF3, BaF3/hEPOR and BaF3/mEPOR cells stably expressing empty MSCVp vector or the indicated
traptamer were incubated in medium lacking IL-3. MSCVp cells were also incubated in the presence of EPO, as indicated. The number of live cells was
counted six days after IL-3 removal. The bars show mean ± SEM for three independent experiments. For clarity, in all graphs, values for samples with no
growth were arbitrarily set at 0.5  104 cells/ml. Statistical significance of differences between cells expressing MSCVp and cells expressing a traptamer
were evaluated by two-tailed Student’s t-test with unequal variance (*p0.05; **p0.02; ***p0.005). (B) BaF3 cells and BaF3 cells expressing wild-type
hEPOR, F8 (a phosphorylation-defective mutant of the hEPOR), mEPOR, PDGFbR or SCFR were infected with MSCVp or MSCVp expressing LH1 or LH5.
After puromycin selection, cells were incubated in medium lacking IL-3. Cells expressing MSCVp were also treated with the cognate ligand, as
indicated: EPO for EPOR and F8, PDGF for PDGFbR, and stem cell factor for SCFR. The number of live cells was counted six days after IL-3 removal.
The bars shown mean ± SEM for three independent experiments. Statistical significance of differences between cells treated with ligand and cells
expressing a traptamer were evaluated by two-tailed Student’s t-test with unequal variance (**p0.02; ***p0.005). (C) Sequence of LH5 starting at
position two is shown at the bottom, with isoleucines colored red. Each leucine was mutated individually to isoleucine and each isoleucine was mutated
to leucine. BaF3, BaF3/hEPOR and BaF3/mEPOR cells were infected with MSCVp or MSCVp expressing LH5 or one of the LH5 mutants. After
puromycin selection, cells were incubated in medium lacking IL-3. In cells expressing a traptamer with a mutation at the indicated position, the number
of live cells was counted six days after IL-3 removal. The bars show mean ± SEM for three independent experiments. For each mutant, statistical
significance of differences between cells expressing hEPOR and cells expressing mEPOR were evaluated by two-tailed Student’s t-test with unequal
variance (**p0.02). (D) Top panel. Schematic diagram of mhm and hmh chimeric receptors with hEPOR and mEPOR segments shown in black and
gray, respectively. Bottom panel. BaF3 cells expressing the hEPOR, the mEPOR, or a chimeric EPOR were infected with MSCVp or MSCVp expressing
the indicated traptamer. After selection with puromycin, cells were tested for IL-3 independence. The number of live cells was counted six days after IL-
3 removal. The bars show mean ± SEM for three independent experiments. Statistical significance of differences between cells expressing wild-type
hEPOR or mEPOR compared to cells expressing a chimeric EPOR were evaluated by two-tailed Student’s t-test with unequal variance (**p0.02).
DOI: https://doi.org/10.7554/eLife.27701.003
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traptamers reported earlier that specifically activate the hEPOR (Cammett et al., 2010;
Cohen et al., 2014). LI-5 (a traptamer that cooperates with the PDGFbR) and several unselected LIL
traptamers did not confer IL-3 independence in BaF3/hEPOR cells (data not shown).
Neither LH1 nor LH5 induced IL-3 independence in cells expressing hEPOR/F8, a phosphoryla-
tion-defective mutant of the hEPOR that does not support EPO-induced proliferation (Wu et al.,
1997) (Figure 2B), suggesting that activation of the EPOR and its downstream signaling pathways
were required for traptamer-induced cell proliferation. To assess specificity, we also co-expressed
LH1 and LH5 with the PDGFbR or the stem cell factor receptor (SCFR), two receptor tyrosine kinases
unrelated to the EPOR. Neither traptamer induced IL-3 independence in cells expressing these
receptors, even though these cells proliferated in response to their cognate ligands (Figure 2B).
Thus, the LIL traptamers studied here specifically activated the EPOR.
Mutational analysis of LH5 identified residues important for activity
and specificity
To explore the basis for traptamer specificity, we conducted a comprehensive mutational analysis of
LH5 by individually replacing each isoleucine with leucine and each leucine with isoleucine, and
tested the activity of the resulting 25 point mutants in parental BaF3 cells or BaF3 cells expressing
the hEPOR or the mEPOR (Figure 2C). None of the mutants were active in parental BaF3 cells. Sev-
eral mutants, for example LH5-I5L, LH5-L14I, and LH5-I16L, failed to cooperate with either EPOR,
demonstrating that a leucine or an isoleucine at particular positions is required for activity. Most
interestingly, the substitutions L9I and I10L dramatically changed the specificity of LH5: LH5-L9I
cooperated with the hEPOR and not the mEPOR, and LH5-I10L cooperated with the mEPOR but not
the human receptor. These results demonstrate that highly specific protein-protein interactions can
be fine-tuned by changing the position of a single side chain methyl group at specific positions in a
short TM protein with minimal chemical complexity.
Traptamer specificity is determined by the EPOR TMD
Given the entirely hydrophobic nature of LIL traptamers, we hypothesized that their specificity was
due to their ability to recognize sequence differences in the TMD of the EPORs. To assess if the
TMD of the EPOR determined whether it responded to the LH5 mutants, we constructed two chime-
ric EPORs by swapping the TMDs of hEPOR and mEPOR and tested the ability of the chimeras to
respond to various traptamers. In the mhm chimera, the TMD of the mEPOR is replaced with the
TMD of hEPOR, and in the hmh chimera, the TMD of the hEPOR was replaced with the TMD of
mEPOR (Figure 2D, top). EPO and LH5 induced IL-3 independence in BaF3 cells expressing either
of these chimeras (Figure 2D, bottom panel), consistent with the ability of EPO and LH5 to activate
both hEPOR and mEPOR. LH5-I10L, which is specific for the mEPOR, cooperated with hmhEPOR
but not with mhmEPOR, whereas LH5-l9L, which is specific for hEPOR, cooperated with mhmEPOR
and poorly with hmhEPOR. Thus, the ability of the traptamers to discriminate between the hEPOR
and the mEPOR was determined by the amino acid sequence of the EPOR TMD.
Activation of EPOR and JAK2 by LIL traptamers
Tyrosine phosphorylation of the EPOR and its associated JAK2 kinases is a hallmark of EPOR activa-
tion. To determine if the traptamers induced tyrosine phosphorylation of EPOR, lysates were pre-
pared from BaF3/hEPOR and BaF3/mEPOR cells expressing an empty vector, LH5, or one of its
mutants. Lysates were subjected to anti-HA immunoprecipitation to recover the HA-tagged EPOR,
and immunoblotted with a broadly reactive anti-phosphotyrosine antibody. As shown in Figure 3A,
there was little, if any, tyrosine phosphorylation of either hEPOR or mEPOR in cells expressing the
empty vector (lane 1). EPO treatment (lane 2) or expression of LH5 (lane 3) caused tyrosine phos-
phorylation of both hEPOR and mEPOR. However, the two EPORs responded differently to the
mutant traptamers. LH5-L9I caused tyrosine phosphorylation of hEPOR but not mEPOR (lane 4), and
LH5-I10L (lane 5) caused tyrosine phosphorylation of mEPOR but not hEPOR. Thus, EPOR tyrosine
phosphorylation correlated perfectly with the ability of the traptamers to induce growth factor
independence.
Samples were also assayed by immunoblotting with an antibody that detects phosphorylation of
JAK2 at Tyr1008 (Figure 3B). JAK2 phosphorylation displayed the same pattern as noted above for
He et al. eLife 2017;6:e27701. DOI: https://doi.org/10.7554/eLife.27701 5 of 28
Research article Biochemistry Biophysics and Structural Biology
EPOR. Namely, compared to unstimulated cells (lane 1), EPO treatment (lane 2) or expression of
LH5 (lane 3) caused phosphorylation of JAK2 in cells expressing either hEPOR or mEPOR. In con-
trast, LH5-L9I induced JAK2 phosphorylation only in cells expressing the hEPOR (lane 4), and LH5-
I10L induced phosphorylation of JAK2 only in cells expressing the mEPOR (lane 5). Taken together,
Figure 3. Biochemical analysis of EPOR activation. (A) Extracts were prepared from BaF3/hEPOR cells (left panels) or BaF3/mEPOR cells (right panels)
expressing MSCVp (V), LH5, LH5-L9I (L9I), or LH5-I10L (I10L). MSCVp-expressing cells were also acutely treated with EPO, as indicated. Extracts were
immunoprecipitated with anti-HA antibody and immunoblotted with anti-phosphotyrosine antibody PY100 (phospho-EPOR). The multiple species
represent minor phosphorylated forms of the EPOR. The same blot was stripped and reprobed for total EPOR by using anti-HA antibody. (B) Cell
extracts described in panel A were immunoblotted with anti-phospho-JAK2 antibody (phospho-JAK2). The same blot was stripped and reprobed for
total JAK2 using anti-JAK2 antibody. Size of protein markers (in kDa) is shown in A and B. (C) Extracts were prepared from BaF3/hEPOR cells (top
panel) or BaF3/mEPOR cells (bottom panel) expressing MSCVp vector (V), FLAG-tagged LI-5 (a traptamer that specifically activates PDGFbR
[Heim et al., 2015]), or FLAG-tagged (+) or untagged (-) LH5, LH5-L9I, or LH5-I10L. Extracts were immunoprecipitated with anti-FLAG antibody and
immunoblotted with anti-HA antibody. (D) Extracts of BaF3 cells expressing the full-length hEPOR (fl) and/or the D259 truncated hEPOR (t) and the
indicated traptamer or MSCVp (V) were immunoprecipitated with anti-C-20 antibody, which recognizes only full-length EPOR, and immunoblotted with
anti-HA antibody (C-20 IP) (top panel); or were directly immunoblotted with anti-HA antibody (input EPOR) (bottom panel). – indicates no traptamer.
The full-length and truncated EPORs are indicated by the bold and thin arrows, respectively.
DOI: https://doi.org/10.7554/eLife.27701.004
The following figure supplements are available for figure 3:
Figure supplement 1. Expression of FLAG-tagged traptamers and HA-tagged EPOR.
DOI: https://doi.org/10.7554/eLife.27701.005
Figure supplement 2. Addition of a FLAG-tag does not change the specificity of traptamers.
DOI: https://doi.org/10.7554/eLife.27701.006
Figure supplement 3. Defective LH5 mutants do not bind hEPOR.
DOI: https://doi.org/10.7554/eLife.27701.007
Figure supplement 4. Active traptamers bind truncated hEPOR.
DOI: https://doi.org/10.7554/eLife.27701.008
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these data show that the traptamers specifically activate the EPOR signaling pathways to induce
growth factor independence.
Stable association between the active traptamers and the EPO
receptor
We used co-immunoprecipitation to determine whether the traptamers formed a complex with the
EPOR. We first added a FLAG epitope tag to the N-terminus of LH5, LH5-L9I, and LH5-I10L. FLAG-
tagged traptamers were expressed in BaF3 cells together with hEPOR or mEPOR (Figure 3—figure
supplement 1) and displayed the same specificity as their untagged counterparts (Figure 3—figure
supplement 2). The activity of the tagged traptamers implies that they adopt a type II TM orienta-
tion (i.e., N-terminus in the cytoplasm), because it is unlikely that the highly charged N-terminal
FLAG tag can cross the membrane when the traptamers are expressed in cells.
To assess complex formation, detergent lysates of cells expressing various combinations of trap-
tamers and EPORs were immunoprecipitated with anti-FLAG beads and then probed with anti-HA
antibody to detect HA-tagged EPOR associated with FLAG-tagged traptamer (Figure 3C). No
EPOR was immunoprecipitated from cells not expressing a traptamer (lane 1) or expressing an
untagged traptamer (lanes 3, 5, and 7), demonstrating that the anti-FLAG antibody does not cross-
react with the EPOR. Similarly, EPOR was not co-immunoprecipitated from cells expressing FLAG-
tagged LI-5, which activates PDGFbR but not the EPOR (Heim et al., 2015) (lane 2), or from cells
expressing FLAG-tagged defective mutants LH5-L14I or LH5-L20I (Figure 3—figure supplement 3),
highlighting that these traptamers do not associate with the EPOR with sufficient affinity to be
detected in this assay. In contrast, anti-FLAG antibody co-immunoprecipitated the HA-tagged
hEPOR and mEPOR when FLAG-tagged LH5 was expressed in the cells (lane 4), showing that LH5
was indeed in a physical complex with the EPOR. Strikingly, the ability of the LH5 mutants to bind
hEPOR or mEPOR in this assay correlated with their biological activity (Figure 3C): LH5-L9I bound to
only hEPOR (lane 6), and LH5-I10L bound to only mEPOR (lane 8). These results strongly suggest
that LIL traptamers induce EPOR activation through binding to the EPOR, and that the ability of the
LH5 mutants to activate only one form of the EPOR is due to specific binding of the mutants to the
hEPOR or mEPOR.
Traptamers enhance oligomerization of EPO receptor
To determine whether the traptamers induced EPOR dimerization, we conducted co-immunoprecipi-
tation experiments with BaF3 cells co-expressing full-length hEPOR and D259, a C-terminally trun-
cated HA-tagged hEPOR mutant consisting of the extracellular ligand-binding domain and TMD, but
lacking the entire cytoplasmic domain. LH5 and LH5-L9I retained the ability to bind D259, whereas
LH5-I10L was defective, consistent with its inability to bind the hEPOR (Figure 3—figure supple-
ment 4).
BaF3 cells expressing the full-length hEPOR, D259, or both full-length and truncated hEPOR were
maintained in medium containing IL-3. For these co-immunoprecipitation experiments, we used
C-20, an anti-hEPOR antibody that does not recognize D259 because of the deletion. As described
in the methods, we confirmed that the C-20 antibody did not directly immunoprecipitate D259 and
that under these conditions there is little basal dimerization between full-length and truncated
EPOR. BaF3/D259-hEPOR cells were then infected with the empty MSCVp vector, or MSCVp
expressing LH5, LH5-L9I or LH5-I10L. If a traptamer promotes hEPOR dimerization, D259 should be
immunoprecipitated with anti-C-20 due to its association with full-length hEPOR. As shown in lanes
5 and 6 of Figure 3D, top panel, D259 was indeed observed in C-20 immunoprecipitates from cells
expressing traptamer LH5 and LH5-L9I, the two traptamers that interact with hEPOR. In contrast, lit-
tle if any D259 was co-immunoprecipitated from cells infected with MSCVp empty vector (lane 4) or
expressing LH5-I10L (lane 7), which does not interact with the hEPOR. These results demonstrate
that the two traptamers that activate the hEPOR, LH5 and LH5-L9I, induce hEPOR oligomerization,
presumably dimerization, whereas LH5-I10L does not.
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NMR evidence that the active traptamers induce dimerization of the
hEPOR TMD in detergent micelles
To test whether the traptamers affected oligomerization of the EPOR TMD, we used NMR to deter-
mine the effect of adding traptamers to the hEPOR TMD in 1,2-dihexanoyl-sn-glycero-3-phospho-
choline (DHPC) detergent micelles. We used a 61-residue segment of the hEPOR (residues 217 to
277), comprising ~10 residues upstream of the TMD, the TMD itself, and ~30 residues downstream
of the TMD. This segment (hEPOR217-277) was labeled with
15N (or with 13C and 15N) and purified
from bacteria (Bugge et al., 2015). A peptide containing the TMD of the unrelated human growth
hormone receptor (hGHR) (residues 238 to 274) was also labeled and purified. Similarly, we purified
recombinant unlabeled LH5, LH5-L9I, and LH5-I10L.
hEPOR217-277 was reconstituted in DHPC micelles and its backbone NMR resonances were
assigned (Figure 4A). Earlier work showed that the EPOR TMD weakly dimerizes in C14SB detergent
micelles, and similar to other TMDs its monomer-dimer equilibrium is determined by the protein-to-
detergent ratio (Ebie and Fleming, 2007; Mineev et al., 2014). Therefore, the hEPOR217-277 mono-
mer-dimer equilibrium was assayed by monitoring changes in protein backbone chemical shifts upon
DHPC titration. The overlay of spectra at high (red) and low (black) DHPC concentrations showed
clear changes in amide backbone chemical shifts (representative residues shown in Figure 4B). Thus,
a change in equilibrium occurred, likely reflecting a switch of the hEPOR TMD to a more monomeric
state at increasing DHPC. The weighted and combined nitrogen and proton chemical shift changes
per residue (Figure 4C, red bars) revealed numerous residue-specific changes, most of which likely
reflected packing differences with the detergent upon monomerization, most dramatically for resi-
dues close to the detergent head groups. Importantly, the chemical shift changes were not depen-
dent on the concentration of DHPC in the sample but only on the ratio between protein and
detergent (data not shown). Thus, we conclude that these residue-specific changes reflect the oligo-
merization state of the EPOR TMD.
To determine the effect of LH5 on the hEPOR TMD, the LH5 peptide was added at 1:2 and 2:2
molar ratios to hEPOR217-277, while keeping the ratio of total protein to detergent constant. Addition
of LH5 at low DHPC caused the chemical shifts of hEPOR217-277 to change as illustrated by the NMR
signals from Leu230 and Ala245 in the 1H,15N-HSQC spectra (Figure 4B, blue peaks). The same res-
onances were affected by DHPC increase (red) or LH5 addition (blue), but in opposite directions
(Figure 4B and C). Thus, these treatments most likely induce opposite changes in hEPOR217-277,
with DHPC pushing the equilibrium toward the monomer and LH5 pushing it toward the dimer. We
did not observe specific LH5-induced chemical shift changes in the middle of the TMD where LH5
Leu9 and Ile10 appear to interact with the EPOR. However, the interactions of LH5 with hEPOR217-
277 might be primarily side chain directed, as suggested by the mutation data, and thus not observ-
able by backbone amide chemical shifts. In this case, dimerization-induced detergent repacking
would dominate the changes in chemical shift. To further test the effect of LH5 on hEPOR217-277 side
chain chemical shifts, we recorded 13C-HSQCs of 13C,15N-hEPOR217-277 alone and in complex with
LH5. Overall the two spectra aligned very well and no major chemical shift changes were observed
(Figure 4—figure supplement 1A). However, as shown in Figure 4—figure supplement 1B, addi-
tion of the traptamer caused the appearance of two novel peaks. Although we have not assigned
these peaks, they do not appear to belong to hydrophobic side chain atoms, or a serine or threonine
within the TMD, as the chemical shifts specific to the side chains of these residues were identical in
the presence and absence of LH5. Regardless, these data show that the traptamers do change the
chemical environment of a restricted number of side chains in the segment of the hEPOR included in
these experiments.
When the mutant traptamer peptides were added to 15N-labeled hEPOR TMD, the same residues
were affected in the same direction as when LH5 was added, but the amplitudes of the chemical
shift changes in the 15N,1H-HSQC spectra were different (Figure 4—figure supplement 2). In accor-
dance with the inability of LH5-I10L to cooperate with the hEPOR, this peptide induced the smallest
chemical shift changes, whereas LH5-L9I and LH5, which cooperate with hEPOR, induced larger
changes, illustrated for Leu230 and Ala245 in Figure 4D. These experiments indicate that all three
peptides enhance dimerization of the hEPOR TMD, but the LH5 and LH5-L9I peptides were more
active at inducing dimerization, consistent with the ability of the corresponding traptamers to coop-
erate with the hEPOR.
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Figure 4. LH5 drives EPOR TMD peptides into dimers in detergent micelles. (A) 1H,15N- HSQC spectrum of 15N-labelled hEPOR217-277 in DHPC micelles
with assignments indicated. (B) Zoomed-in contour plots of hEPOR Ala245 and Leu230 from 1H,15N- HSQC spectra. Peaks from hEPOR217-277 at 30-
times molar excess of DHPC are depicted in black, peaks at 60-times molar excess of DHPC in red, and peaks with LH5 in a ratio of LH5:hEPOR:DHPC
of 1:1:30 in blue. Increasing the amounts of DHPC or adding LH5 induced opposite effects as indicated by arrows. (C) Weighted chemical shift changes
of 15N-hEPOR217-277 backbone amides per residue upon increasing the molar excess of DHPC from 30 to 60 times (red bars) or addition of LH5 in a
molar ratio of 1:1 (blue bars). The same residues were affected by LH5 and DHPC, but the peaks move in opposite directions. The hEPOR TMD is
indicated by a black horizontal line. Diamonds on the x-axis indicate proline residues, overlapping peaks, and missing assignments. (D) Weighted
chemical shift changes of Leu230 and Ala245 backbone amides induced by addition of LH5, LH5-L9I or LH5-I10L at molar ratios of one traptamer
molecule to two hEPOR TMDs (1:2) and two traptamer molecules to two hEPOR TMDs (2:2). (E) Weighted chemical shift changes of 15N-hEPOR217-277
Ala245 and Leu230 backbone amides induced by addition of LH5 at different molar ratios of LH5 to hEPOR217-277 in DHPC micelles. Two individual
titrations were performed, one from 0:1 to 1:1 (corresponding to the 2:2 traptamer:EPOR TMD ratio) and the other from 0:1 to 4:1 (corresponding to
the 8:2 traptamer:EPOR TMD ratio) molar ratio of LH5 to hEPOR217-277. The titration point at 1:1 was recorded in each series. A hyperbola is indicated
to guide the eye. (F) 1H,15N- HSQC spectrum of 15N-labelled hGHR238-274 in DHPC micelles. (G) Zoomed-in contour plots of two selected peaks of
hGHR from 1H,15N- HSQC spectra. Peaks from hGHR238-274 at 60-times molar excess of DHPC are depicted in black, peaks at 120-times molar excess of
DHPC in red, and peaks with LH5-L9I in a ratio of LH5-L9I:hEPOR:DHPC of 2:1:60 in blue. Addition of LH5-L9I did not induce a change in chemical shifts
as indicated by the near-complete overlap of the black and blue peaks (Figure 4—figure supplement 3). The extent of the chemical shift changes in
the hGHR238-274 spectra is illustrated in the bar graphs showing the changes induced by the DHPC in red and by LH5-L9I in blue for the peaks shown on
the left.
DOI: https://doi.org/10.7554/eLife.27701.009
The following figure supplements are available for figure 4:
Figure supplement 1. hEPOR TMD side chain chemical shift.
DOI: https://doi.org/10.7554/eLife.27701.010
Figure supplement 2. LH5 mutants drive hEPOR TMD peptides into dimers.
Figure 4 continued on next page
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The differential ability of LH5-L9I and LH5-I10L to drive dimerization of the hEPOR TMD implies
that this is a sequence-specific effect mediated by direct interactions between the TMDs, rather than
by the traptamers changing the lipid/detergent environment of hEPOR TMD. If it is a direct effect,
we predict that the traptamers would exert a saturable effect on the NMR spectra of the EPOR
TMD, and additionally would not affect the TMD of an unrelated receptor. To test these predictions,
we added traptamers at various ratios to hEPOR217-277 and measured the induced chemical shift. As
shown in Fig, 4E, the NMR shifts were clearly saturable at a traptamer-to-EPOR TMD ratio approach-
ing 2 (as it would be for the 4:2 complex). Because of the small, induced chemical shift changes and
the possibility of the experiment not being conducted at concentration well above KD, we cannot
assign a precise stoichiometry to the complex. Nevertheless, these results show that more than one
and possibly four traptamer helices associate with each EPOR TMD dimer. Importantly, the saturabil-
ity of this process shows that we observe a direct interaction rather than an indirect effect upon
addition of LH5. We also investigated whether the equilibrium of the TMD of an unrelated receptor,
the human growth hormone receptor (hGHR), was affected by LH5-L9I, the traptamer mutant that
had the greatest effect on the hEPOR TMD. NMR spectra were obtained for the TMD of the hGHR
in the presence and absence of LH5-L9I and at different protein-to-DHPC ratios (Figure 4F and G).
As shown in Figure 4G and Figure 4—figure supplement 3A, DHPC titration had a marked effect
on several hGHR chemical shifts. In contrast, LH5-L9I had little or no effect on the hGHR TMD chemi-
cal shifts (Figure 4G and Figure 4—figure supplement 3B), demonstrating that LH5 traptamers
specifically stabilize hEPOR dimerization.
We also considered the possibility that the observed dimerization effect could be caused by LH5
titrating DHPC away from hEPOR217-277, thereby indirectly shifting the monomer:dimer equilibrium
towards the dimer. However, the leucine or isoleucine substitution in the traptamer mutants would
not modulate the hydrophobicity of LH5 to an extent that this effect could account for the diverse
chemical shift changes observed. In addition, it seems likely that such an indirect effect would also
affect the hGHR TMD. We thus conclude that the traptamers directly stabilize the dimeric form of
the hEPOR TMD.
Residue at position 10 of traptamer LH5 plays an important role in
determining specificity
We next sought to identify specific amino acids responsible for productive interaction between LH5
and the EPOR TMDs. We constructed LH5 mutants containing all combinations of leucine, isoleucine,
valine and alanine at position 9 and 10 and tested the ability of these 16 proteins to cooperate with
hEPOR or mEPOR in BaF3 cells. Valine is structurally similar to isoleucine except it lacks a terminal
methyl group, and alanine has a small aliphatic side chain. The ability of a traptamer to cooperate
with the hEPOR was determined solely by the presence of an isoleucine at position 10. Traptamers
with an isoleucine at this position cooperated with the hEPOR, whereas mutants containing a leu-
cine, valine, or alanine at position 10 displayed little if any ability to cooperate with the hEPOR (Fig-
ure 5, top panel). In contrast, the chemistry of the amino acid at position nine did not affect activity.
Position 10 was also a prime determinant of activity with the mEPOR (Figure 5, bottom panel). Trap-
tamers with leucine in position 10 cooperated with the mEPOR, regardless of the amino acid at posi-
tion 9. Traptamers with isoleucine at position 10 activated the mEPOR only if they also contained a
leucine or alanine at position 9. Traptamers with valine or alanine at position 10 did not cooperate
with the mEPOR. Thus, the amino acid at position 10 was the prime determinant of specificity.
A small amino acid at position 238 in the TMD of the mEPOR
determines specificity
The sequence of the TMD of mEPOR differs from that of hEPOR at three positions, Leu236 in place
of valine, Ser238 in place of leucine, and Leu239 in place of valine (the numbering throughout is
Figure 4 continued
DOI: https://doi.org/10.7554/eLife.27701.011
Figure supplement 3. LH5-9LI does not change the growth hormone receptor monomer-dimer equilibrium.
DOI: https://doi.org/10.7554/eLife.27701.012
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based on the hEPOR sequence) (Figure 6A). To identify the residues in the TMD of the mEPOR that
dictate the specificity of the traptamers, we tested the effect of all three mouse-to-human single
substitution mutations in the TMD of mEPOR. Cells expressing these mutants did not proliferate in
Figure 5. Mutational analysis of traptamer at positions 9 and 10. BaF3 cells expressing the hEPOR (upper panel) or
the mEPOR (lower panel) were infected with MSCVp expressing wild-type LH5 or mutants containing all
combinations of isoleucine, leucine, valine, and alanine at positions 9 and 10. After puromycin selection, cells were
tested for IL-3 independence. The right axis indicates the residue at position 10. The horizontal axis indicates the
residue at position 9. The vertical axis shows the number of live cells six days after IL-3 removal. The bars
representing cells expressing LH5, LH5-L9I, and LH5-I10L are labeled. The bars show mean ± SEM for three
independent experiments. The results for the LH5 sample were significantly different (p0.005, as assessed by
two-tailed Student’s t-test) compared to cells expressing each mutant, except for the mutants with isoleucine at
position 10 (top panel) or leucine at position 10 and LH5-L9A (bottom panel).
DOI: https://doi.org/10.7554/eLife.27701.013
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Figure 6. Identification of amino acids that mediate complex formation between the traptamers and the EPOR. (A) Sequence comparison of hEPOR
and mEPOR TMD (residue 226–247). Sequence differences between mEPOR and hEPOR are shown in red. (B) BaF3 cells or BaF3 cells expressing the
wild-type mEPOR, the wild-type hEPOR, or the mEPOR containing the indicated mutation were infected with retroviruses expressing the indicated
traptamer. After puromycin selection, the cells were tested for IL-3 independence. The number of live cells was counted six days after IL-3 removal. The
bars show mean ± SEM for three independent experiments. Statistical significance of differences between cells expressing wild-type mEPOR and cells
expressing a mutant mEPOR were evaluated by two-tailed Student’s t-test with unequal variance (**p0.02). (C) Left panel. BaF3 cells expressing wild-
type hEPOR, L238S hEPOR mutant, or mEPOR were infected with retrovirus expressing FLAG-tagged LH5 or LH5-I10L. After puromycin selection, cells
were tested for IL-3 independence. The number of live cells was counted six days after IL-3 removal is shown. The bars show mean ± SEM for three
independent experiments. Statistical significance of differences between cells expressing wild-type hEPOR and cells expressing hEPOR/L238S were
evaluated by two-tailed Student’s t-test with unequal variance (***p0.005). Right panel. Extracts prepared from cells in left panel were
immunoprecipitated with anti-FLAG antibody and immunoblotted with anti-HA antibody to detect EPOR associated with traptamer (top panel), or
directly immunoblotted with anti-HA antibody to detect total EPOR (bottom panel). (D) BaF3 cells expressing wild-type mEPOR (238S) or the indicated
mEPOR mutant were infected with retrovirus expressing LH5 or LH5-I10L. After puromycin selection, IL-3 independence was tested. The number of live
cells was counted six days after IL-3 removal. The bars show mean ± SEM for three independent experiments. Statistical significance of differences
between cells expressing wild-type mEPOR and cells expressing an mEPOR mutant were evaluated by two-tailed Student’s t-test with unequal variance
(**p0.02). (E) Left panel. BaF3 cells co-expressing FLAG-tagged LH5-I10L or LH5-I10S (horizontal axis) and the wild-type mEPOR or S238L mEPOR
mutant (right axis) were tested for IL-3-independence. The vertical axis shows the number of live cells six days after IL-3 removal. The parental
combination (mEPOR/LH5-I10L) is shown in light grey bar; the compensating combination (mEPOR S238L/LH5-I10S) is shown in black bar. The bars
show mean ± SEM for three independent experiments. Statistical significance of differences between cells co-expressing both mutants and cells
expressing either single mutant was p0.05 as evaluated by two-tailed Student’s t-test with unequal variance. Right panel. Extracts prepared from cells
in left panel were immunoprecipitated with anti-FLAG antibody and immunoblotted with anti-HA antibody to detect EPOR associated with traptamer
(top panel), or directly immunoblotted with anti-HA antibody to detect total EPOR (bottom panel).
DOI: https://doi.org/10.7554/eLife.27701.014
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IL-3-free medium, demonstrating that they were not constitutively active (data not shown). As
expected, LH5 cooperated with all three mutants (Figure 6B).
We determined whether these mutations affected the activity of the traptamer mutants. The
activity of LH5-I10L was not affected by the mutation at position 236 or 239 in the mEPOR
(Figure 6B). In contrast, the S238L mutation completely abrogated the ability of the mEPOR to
respond to LH5-I10L, showing that Ser238 was important for specific recognition of the mEPOR by
LH5-I10L (Figure 6B). To confirm the role of Ser238 in determining traptamer specificity, we mutated
Leu238 in the hEPOR to serine and tested the response of this mutant to LH5-I10L. As shown in
Figure 6C, left panel, LH5-I10L induced IL-3 independence in cells expressing the L238S hEPOR but
not wild-type hEPOR. In addition, LH5-I10L formed a stable complex with the L238S hEPOR mutant
but not with wild-type hEPOR (Figure 6C, right panel). Thus, the absence of serine at position 238 in
the TMD of hEPOR is the sole reason why hEPOR does not respond to LH5-I10L.
The analysis of LH5-L9I activity with these mutants was not straightforward. The L236V mEPOR
mutant displayed the greatest ability to cooperate with LH5-L9I, but the S238L and L239V mutants
displayed moderate ability to support LH5-L9I-mediated IL3-independent growth (Figure 6B). Thus,
several residues in the EPOR TMD controlled the response to LH5-I9L. Because of the secondary
importance of position nine in determining traptamer specificity (Figure 5), we did not pursue the
analysis of this position further.
We next determined which structural feature of Ser238 was required for activity with LH5-I10L.
We mutated Ser238 to either of two small aliphatic residues, alanine and glycine, or to the polar resi-
due threonine, which contains a side chain hydroxyl group like serine but is one methyl group larger.
None of the mutants constitutively induced IL-3 independence (data not shown), and all were acti-
vated by LH5, as shown in Figure 6D. Traptamer LH5-I10L induced IL-3 independence with the wild-
type mEPOR and with the S238A and S238G mEPOR mutants. Thus, alanine or glycine can replace
serine at position 238, demonstrating that the serine hydroxyl group is not important for activity in
this assay. In contrast, LH5-I10L did not cooperate with the S238T mEPOR mutant, suggesting that
the size of the side chain at position 238, rather than hydrophilicity, determined the ability of LH5-
I10L to productively interact with the mEPOR.
Compensatory mutations within the TMD of the EPOR receptor and a
traptamer
The results described above raised the possibility that the long side chain at position 10 in the trap-
tamer directly interacted with the short side chain of mEPOR TMD at position 238. If the residues at
traptamer position 10 and mEPOR position 238 interact directly, we hypothesized that simulta-
neously swapping the residues at both of these positions might restore biological activity. We first
tested the activity of a LH5 mutant with serine at position 10. As shown in Figure 6E (left panel),
LH5-I10S did not cooperate with wild-type mEPOR to induce IL-3 independence. Strikingly, however,
LH5-I10S cooperated with mEPOR/S238L to restore a significant level of IL3-independence
(Figure 6E, left panel, black bar). Thus, LH5-I10S did not cooperate with the wild-type mEPOR and
LH5-I10L did not cooperate with mEPOR S238L, but LH5-I10S did cooperate with mEPOR S238L.
We also conducted co-immunoprecipitation experiments for the four combinations of proteins.
As shown in Figure 6E (right panel), complex formation between mEPOR and LH5-I10L was abro-
gated by mutating position 10 in the traptamer to serine (lane 2) or by mutating Ser238 to leucine in
the TMD of the mEPOR (lane 3). Notably, simultaneous mutation of position 10 of the traptamer and
position 238 of the mEPOR restored complex formation (lane 4), consistent with restoration of bio-
logical activity by this combination of mutations. Restoration of activity by compensating mutations
also implies that the defect of the position S238L mEPOR mutant is caused by direct disruption of
the interaction with the traptamer and not, for example, by an indirect effect of the mutation on the
receptor itself. Taken together, these results provide strong genetic evidence that the two proteins
contact each other directly and suggest that this interaction is mediated by contacts between the
side chains at position 10 in the traptamer and position 238 in the TMD of the mEPOR.
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Traptamers remodel the conformational landscape of EPOR TMD
dimers in simulations
The TMD of the mEPOR (and to a lesser extent, the hEPOR) has intrinsic ability to homodimerize
(Ebie and Fleming, 2007; Kubatzky et al., 2001; Ruan et al., 2004; Li et al., 2015). In addition to
dimerization, the conformational state of the dimeric EPOR TMDs regulates activity (Moraga et al.,
2015; Seubert et al., 2003). We thus used molecular dynamics (MD) simulations in an implicit mem-
brane to determine whether traptamers may affect the conformation of EPOR TMDs within the
dimer. Innate conformational preferences of mEPOR and hEPOR TMD dimers were first established
by simulating these in the absence of traptamers (total simulation time of 1 ms; see
Materials and methods). Ten independent simulations were run for each receptor, and inter-helical
geometries in resulting trajectories were analyzed, focusing on helical phase. This parameter
describes the rotation of individual TM helices about their helical axes, thus defining which helical
faces pack into the dimer interface (Grigoryan and Degrado, 2011). Prior analysis (Seubert et al.,
2003) implies that close-to-symmetric configurations are likely most relevant in the context of the
full-length EPOR, so we concentrated our analysis on these states. The helical phase distributions
Figure 7. Molecular modeling of the effect of the traptamers on the EPOR TMD. (A) Helical phase distributions of hEPOR (left) and mEPOR (right) TMD
dimers in the absence of traptamer (black lines) or in 2:2 stoichiometry with LH5 (red lines), LH5-L9I (blue lines) or LH5-I10L (green lines). The range of
the x-axis is from  180˚ to 180˚, with labeled ticks denoting phase boundaries corresponding to canonical coiled-coil heptad registers, labeled I
through VII. (B) Helical wheel diagrams of mEPOR TMD dimers corresponding to the basal states II, IV, and V, as well as state III, which is appreciably
populated only in the presence of traptamers. Ser238 is colored green. (C) A diagram of state III (gray and blue circles represent EPOR TMDs and
traptamers, respectively), showing the helical phase distributions from simulations of hEPOR (left panel) and mEPOR (right panel) TMD dimers in
complex with LH5. Phase distributions are plotted in polar coordinates (rosette plots): each dot representing a bin in the histogram, with its location
around the circle indicating the phase value and its distance from the helix center denoting the frequency of the bin (points farther from the center are
more frequent).
DOI: https://doi.org/10.7554/eLife.27701.015
The following figure supplements are available for figure 7:
Figure supplement 1. Helical wheel diagrams and helical phase distributions of mEPOR TMD dimers.
DOI: https://doi.org/10.7554/eLife.27701.016
Figure supplement 2. Time to approach symmetry.
DOI: https://doi.org/10.7554/eLife.27701.017
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within such pseudo-symmetric conformations for both the hEPOR and mEPOR TMD are shown in
Figure 7A (black curves), with states corresponding to canonical coiled-coil heptad registers
(Grigoryan and Degrado, 2011) labeled with Roman numerals (see Figure 7B and Figure 7—figure
supplement 1 for corresponding helical wheel diagrams). Two states dominated both hEPOR and
mEPOR: one corresponding to register II and the second involving registers IV and V. These states
placed polar serine and threonine side chains in the dimer interface, enabling interhelical hydrogen
bonds. Published work suggests that these EPOR TMD orientations do not result in robust down-
stream signaling (Seubert et al., 2003).
We next asked if these state distributions were perturbed by the traptamers. We considered
ratios of one, two, or four traptamer molecules per EPOR TMD dimer (designated 1:2, 2:2, and 4:2,
respectively), with traptamers inserted in the membrane anti-parallel to EPOR TMDs. In addition,
traptamers were restrained to remain in the proximity of the dimeric EPOR TMDs. Figure 7A shows
the helical phase distributions for EPOR TMD dimers in the presence of LH5 (red line), LH5-L9I (blue
line), or LH5-I10L (green line) in the 2:2 stoichiometry. Introduction of traptamers caused substantial
remodeling of the conformational landscape of the EPOR TMD dimers, as it did in the other stoichio-
metries we tested (see Figure 7—figure supplement 1B). Notably, state III was nearly unpopulated
with EPOR TMD dimers alone, but was sampled robustly in the presence of the traptamers. In state
III, residue 238 of EPOR TMD mapped to a g position, making it available for quaternary interactions
with traptamers (Figure 7B; Ser238 labeled green), consistent with the experimentally-observed
importance of position 238 in traptamer action. In contrast, in basal states IV and V, residue 238 was
buried in the TMD dimer interface and therefore not accessible to the traptamer(s) and in basal state
II, residue 238 was in position c far from the EPOR dimer interface. Remarkably, the placement of a
single side chain methyl group at traptamer position 9 or 10 affected the phase distributions. For
example, state IV in the hEPOR was populated in response to LH5 and LH5-L9I, but not in response
to LH5-I10L. However, in the modeling there was no evident correlation between the biological
activity of the wild-type and mutant traptamers against the different species of the EPOR and the
ability of the traptamers to induce specific orientations of the EPOR TMDs. This is presumably
because the biological activity of a particular mutant/EPOR combination arises from the ability of the
traptamer to bind the EPOR, induce EPOR dimerization, and to trap it in a functional orientation,
whereas our simulations capture only the latter effect because the sampling was limited to the asso-
ciated state only.
To better understand how traptamers remodel the state distribution of EPOR TMDs, we consid-
ered state III, which is most clearly modulated in response to traptamers. We identified all snapshots
from all trajectories that map to state III and extracted helical phases corresponding to position 238
in the EPOR TMD and positions 9 and 10 in the traptamers; these are represented as rosette plots in
Figure 7C for hEPOR/LH5 and mEPOR/LH5 complexes. This analysis shows that positions 9 and 10
spend much of their time oriented towards the EPOR TMD, in a phase orientation that could enable
them to engage EPOR position 238. In fact, analysis of simulation trajectories revealed that positions
9 or 10 are within van der Waals contact of position 238 (for at least one of the TMD helices) in 55%
to 97% of all state-III trajectory snapshots, across all traptamers in all three tested stoichiometries.
This is consistent with our genetic findings that TMD position 238 and traptamer positions 9 and 10
play crucial roles in establishing traptamer specificity in cells. Figure 7C also shows that there is con-
siderable heterogeneity in traptamer rotational state, which suggests that traptamers act in a much
more dynamic fashion than may typically be expected of signaling modulators. That is, rather than
being frozen in a single preferred configuration with respect to the EPOR TMD dimer, traptamers
appear to adopt a variety of orientations, yet still making specific contacts with the EPOR TMD and
having a net effect of perturbing its conformational equilibrium.
NMR data suggest that EPOR TM dimers are symmetric, with or without traptamers, whereas we
observe that many individual snapshots sampled in MD trajectories are significantly non-symmetric.
Indeed, MD simulations showed that traptamers rapidly inter-convert between different helical
phases in all stoichiometries, such that complexes can be expected to be symmetric only in an aver-
age sense. In fact, analysis of our MD trajectories revealed that all simulations are consistent with
complexes approaching symmetry much faster than the typical ms NMR time scales (see Figure 7—
figure supplement 2).
Overall, these simulations demonstrated that traptamers significantly remodel the conformational
landscapes of EPOR TMD dimers, shifting the populations towards states in which TMD position 238
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interacted with traptamer residues 9 and 10. Furthermore, subtle chemical differences between trap-
tamers can have dramatic consequences on this orientation. We point out that we have not estab-
lished which EPOR TMD state is most relevant for EPOR activation by the traptamers, what the
correct EPOR-traptamer stoichiometry is or, indeed, that there even is a single well-defined stoichi-
ometry. Nevertheless, our results strongly suggest that the active LIL traptamers exhibit their func-
tional effects through structurally specific interactions with the EPOR TMDs, even though they are
likely to be dynamic and adopt a variety of conformations in complex with their target TMDs, consis-
tent with their low information-content sequences.
All-atom simulations of the EPOR/traptamer complexes
Because the impact of lipids and water on interactions between the traptamers and the EPOR TMDs
was not captured by the implicit modeling, we performed explicit-solvent all-atom MD simulations
of the active and mutant traptamer-EPOR systems in 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocho-
line (POPC) bilayers. Representative 2:2 centroid models obtained from the implicit membrane-
based simulations were used as starting points for all-atom simulations after adding short juxtamem-
brane domains to each end of the TMDs of the receptors. The helices were not restrained to remain
associated in this modeling. After equilibration of the protein-bilayer system for 7 ns, each simulation
was carried out for 50 ns (production run) in Gromacs 2016.1 in duplicate, with different random
seeds. Although the resulting trajectories are not long enough to observe significant inter-state con-
versions of EPOR TMD dimers as with implicit-solvent simulations, several features of EPOR/trap-
tamer complex were evident.
The EPOR TMDs remained associated with each other and with traptamers for the duration of
the simulation in all systems and all replicates. Backbone root-mean-square-deviation (RMSD) of the
hEPOR TMD, relative to the equilibrated conformation, increased significantly in the presence of the
parental LH5 traptamer, underscoring the dynamic nature of the complex, whereas the mEPOR TMD
was much less dynamic than the hEPOR (Figure 8A). When the root mean square fluctuation (RMSF)
of individual residues were compared, these striking differences in the dynamics of the hEPOR and
mEPOR TMDs in the presence of LH5 were distributed along the entire length of the TMDs in both
complexes (Figure 8B). Compared to LH5, the mutant traptamers caused a marked reduction in the
dynamics of the hEPOR TMD along the length of the hEPOR TMD (Figure 8A, top, and Figure 8C).
In contrast, dynamics of the mEPOR TMD were similar in the presence of LH5 and its mutants
(Figure 8A). All of these trends were observed in both independent simulation replicas performed in
each system. This analysis showed that the hEPOR and mEPOR TMDs responded differently to the
traptamers and that repositioning a single methyl group in a traptamer can markedly affect the
dynamics of the hEPOR TMD dimer along its entire length.
Discussion
By studying simple model TM proteins, we discovered that interactions between TMDs can display
high specificity in mammalian cells that can be precisely modulated by minimal structural differences
in the interacting helices. The small size and chemical simplicity of the traptamers allowed us to ana-
lyze the basis for specificity in the absence of confounding factors such as contributions from protein
segments outside of the membrane or hydrogen bonding between hydrophilic amino acid side
chains. We discovered that single leucine-isoleucine substitutions at two positions in a traptamer,
which change the placement of single methyl groups, determined whether it bound and activated
the hEPOR, the mEPOR, or both receptors. Furthermore, corresponding changes on the receptor
rescued activity. Because of the low sequence complexity of the traptamers and the minimal chemi-
cal differences that confer specificity, their ability to distinguish between the hEPOR and mEPOR is
intriguing and potentially implies that entirely novel design principles can modulate the activity of
TM proteins.
How does a protein composed of a 25-residue sequence of two similar hydrophobic amino acids
activate a specific cellular target and discriminate between two closely related targets based on the
placement of a single side chain methyl group in the sequence? Our data show that traptamer action
is mediated by direct binding to the EPOR TMD. The biological activity of LH5 and its mutants corre-
lates perfectly with their ability to associate with the hEPOR or mEPOR, the ability of the traptamers
to activate the EPOR is determined by the sequence of the EPOR TMD, and the isolation of
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compensatory mutations in the traptamer and the mEPOR TMD constitutes formal genetic proof of
a direct interaction. Finally, the molecular modeling and NMR studies provided additional evidence
that the traptamers specifically interact with the EPOR TMD in simplified systems lacking other pro-
teins. We therefore conclude that direct binding of the traptamers to the EPOR is mediated by com-
plementarity between hydrophobic surfaces generated by the sequence of leucines and isoleucines
Figure 8. All-atom simulations of the EPOR/traptamer complexes. (A) RMSD profiles for the EPOR TMDs for the various receptor and traptamer
systems. RMSD values for hEPOR (top panel) and mEPOR (bottom panel) over time in the presence of LH5 (blue line), LH5-L9I (black), and LH5-I10L
(red) were computed for the backbone atoms within the EPOR TMD with respect to their starting structures. (B) Per-residue RMSF profiles of the hEPOR
(solid line) and mEPOR (dashed line) TMDs in the presence of LH5 over 50 ns of production run. Comparisons for each TMD in the dimer are depicted
in separate panels. The membrane-spanning sequence of hEPOR (L226-L247) is shown below the bottom panel, with the residues differing in the
mEPOR shown below it. Leu238 and Ser238 in hEPOR and mEPOR, respectively, are highlighted in green. (C) Difference in per-residue RMSF for the
TMDs of the hEPOR in presence of the mutant traptamers relative to the hEPOR-LH5 traptamer complex (computed over 50 ns of production run).
Differences between LH5 and LH5-L9I and between LH5 and LH5-I10L are plotted as black and red bars, respectively, and depicted in separate panels
for each hEPOR TMD. The membrane-spanning sequence of the hEPOR (L226-L247) is shown below the bottom panel with Leu238 highlighted in
green.
DOI: https://doi.org/10.7554/eLife.27701.018
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in the traptamer and the sequence of the EPOR TMD. There are more than 33 million (225) possible
25-residue sequences of leucine and isoleucine, suggesting that even such short, simple proteins can
generate a large number of surfaces and thus potentially interact with a wide variety of target
proteins.
The discovery of LH5 mutants that activate only the hEPOR or the mEPOR eliminates many trivial
explanations for the specificity of the traptamers. Thus, the inability of such mutants to activate a
particular EPOR is not the result of poor expression, incorrect localization, gross misfolding or major
structural rearrangement or aggregation of the mutant traptamer, or of differential partitioning of
the membrane into domains resulting in non-specific EPOR clustering and activation. Rather, our
results strongly argue that the traptamers act by making specific, yet dynamic, contacts with the
EPOR TMDs and that the amino acids at positions 9 and 10 in the traptamer and at specific positions
in the EPOR TMD play key roles in this interaction, ultimately manifesting in differential ability to
activate the human or mouse EPOR. Because van der Waals interactions require precise geometry
and spacing, moving a methyl group at position 9 or 10 in LH5 one carbon closer or farther from the
polypeptide backbone, respectively, generates a novel surface that is now complementary to only
the hEPOR or the mEPOR, thereby altering specificity. Thus, the methyl group at these positions is
acting as a molecular toggle switch to determine traptamer specificity. The ability of a traptamer to
toggle back and forth between closely related targets in response to the placement of a single
methyl group implies that the determinants of specificity within a membrane are controlled by mini-
mal chemical differences.
The addition of the traptamers did not result in additional significant changes in the backbone
NMR chemical shifts besides those resulting from dimerization. This observation suggests that the
LIL traptamers have lipid-like chemical properties because of their low-complexity sequence contain-
ing purely hydrocarbon side chains, a feature which may favor dynamics in binding and allow for
diversity in stoichiometry. It is therefore possible that traptamer:TMD complexes form un-conven-
tional dynamic complexes, similar to the fuzzy interactions recently described for intrinsically disor-
dered proteins (Klein et al., 2003; Mittag et al., 2008; Olsen et al., 2017), which may nevertheless
still be of high affinity. The ability of the traptamers to productively interact in a highly specific man-
ner with particular EPOR TMDs suggests that such dynamic interactions can also display high speci-
ficity in membranes. A route by which the traptamers would avoid non-specific interactions might be
through a competition between the association of hetero- and homo-oligomeric complexes of EPOR
as well as of the traptamer. The lipid-like properties of the traptamers may lead to the formation of
traptamer polymer-islands in the membrane, implying that in order to bind a certain receptor, the
traptamer:receptor interaction needs to be stronger than the internal affinity between traptamers
and between the EPOR TMDs dimers in their inactive state.
Although the oligomerization state of the traptamer itself is not known, our co-immunoprecipita-
tion and NMR experiments indicate that traptamer binding drives the EPOR toward the oligomeric,
likely dimeric, form. Signaling by the EPOR is dependent on the orientation of its TMDs and linked
cytoplasmic domains (Moraga et al., 2015; Seubert et al., 2003; Syed et al., 1998; Remy et al.,
1999). In the absence of ligand, the TMDs of the mEPOR are in an inactive orientation stabilized by
hydrogen bonds across the homodimer interface ([Ruan et al., 2004; Seubert et al., 2003; Li et al.,
2015], and our MD results), but when the mEPOR dimer is in an active conformation Ser238 appears
to be oriented away from this interface (Seubert et al., 2003). This implies that the traptamers not
only stabilize the EPOR dimer but also cause it to adopt a productive orientation. Consistent with
this interpretation, our implicit-membrane MD simulations indicate that the traptamers induce a frac-
tion of the mEPOR TMDs to re-orient from an inactive orientation into one where Ser238 engages
the traptamer via van der Waals interactions. Because of uncertainties in the stoichiometry of the
complex, among other parameters, we cannot identify with certainty the active orientation, but
rather our results imply that binding of the traptamers is likely to reorient the EPOR TMD from an
inactive orientation into an active one. The differential response of the mEPOR and the hEPOR to
the traptamers in the all-atom MD simulations raises the possibility that there are differences in the
mechanisms by which the traptamers activate the two species of the EPOR.
The small size and chemical simplicity of the traptamers allowed us to interrogate all possible leu-
cine-isoleucine substitutions in LH5. The results of these experiments established that specificity is
determined by repositioning the methyl group at only a limited number of positions in LH5, whereas
mutations that inhibit activity against both EPORs are distributed throughout the sequence. These
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results imply that the interaction of LH5 with the EPOR TMD is stabilized by multiple weak van der
Waals interactions along the length of the TM helices, which, in aggregate, are sufficient to over-
come the interhelical hydrogen bonds that stabilize the inactive conformations of the EPOR TMD. In
such an association driven by shape complementarity, moving a single methyl group at numerous
positions can cause steric clashes that disrupt or weaken the binding of the traptamer to the TMD of
both the hEPOR and the mEPOR. In contrast, mutations at a few positions fine-tune specificity by
generating surfaces that bind strongly to the TMD of only the hEPOR or the mEPOR, while retaining
the ability to induce EPOR TMD dimerization and reorientation. Interestingly, the all-atom simula-
tions demonstrated that the single leucine-isoleucine substitutions in the mutant traptamers gener-
ate conformational differences along the length of the hEPOR TMDs, showing that the structural
consequences of these seemingly simple changes can be complex. We note that substitutions at
positions 2 and 3 in LH5 also resulted in preferential activation of the hEPOR and the mEPOR,
respectively, although the differences were not as dramatic as those caused by the L9I and I10L
mutations (Figure 2C). Because every seventh residue is on the same face of a TM coiled-coil, posi-
tions 2 and 9 are on one face of the TMD helix, and positions 3 and 10 are on a different face, imply-
ing that these two faces play particularly important roles in determining specificity.
Detailed analysis of a single traptamer does not provide a complete picture of the TM interac-
tions that can drive EPOR activation. The active traptamers fall into two classes. LH1 to LH4 activate
only the hEPOR, and LH5 activates both hEPOR and mEPOR. As shown in the boxes in Figure 1B,
LH5 differs from the other traptamers at eleven positions, including the major specificity-determining
positions 9 and 10. These striking sequence and specificity differences suggest that these two clas-
ses of traptamers interact with the hEPOR in fundamentally different ways, presumably though the
formation of different interaction surfaces or different oligomeric states.
By developing a genetic system to study small TM proteins consisting of only leucines and isoleu-
cines, we discovered that highly specific interactions can be fine-tuned by extremely subtle chemical
differences confined to the membrane spanning segment and that this specificity can be driven
exclusively by van der Waals interactions. The traptamers were not subjected to natural selection to
eliminate undesired activities or interactions, implying that this high specificity is an intrinsic property
of TMDs in the context of membrane lipids. This may be particularly true for TMDs that consist
exclusively of hydrophobic residues, whose interaction partner(s) is dictated solely by shape comple-
mentarity along the length of the interacting helices. In contrast, hydrophilic amino acids can form
interhelical hydrogen bonds or ionic interactions, in which interacting side chains may be sufficient
to drive alternative TMD associations (Choma et al., 2000; Zhou et al., 2000).
Although we studied extremely simple model transmembrane proteins, the principles uncovered
here are likely to apply to at least some naturally occurring TMDs. For example, the TMD of the BPV
E5 protein contains a stretch of 12 consecutive residues comprised exclusively of leucine and phenyl-
alanine, and the TMD of the human colony stimulating factor receptor contains a conserved homo-
polymeric stretch of 10 consecutive leucines. In addition, the TMD of the PDGF b receptor contains
diverse amino acids, but a leucine to isoleucine mutation in the middle of this TMD prevents binding
of the E5 protein (Edwards et al., 2013). Our results imply that naturally occurring TMD interactions
based on shape complementarity would also display very high specificity, unless there was an evolu-
tionary advantage to relax this specificity. During evolution, incorporation of a limited number of
hydrophilic amino acids into TMDs consisting of otherwise hydrophobic amino acids may allow
homologous interactions with a family of related but not identical TMDs containing hydrophilic resi-
dues, or may generate higher affinity interactions, even if that comes at the cost of reduced specific-
ity. Our findings also show that supposedly conservative polymorphisms or mutations in TMDs can
have profound effects on TM protein function and should be strictly evaluated for this possibility.
These features of TMD interactions may also inform the design of biologically active TM proteins.
Finally, our results suggest that agents including small hydrophobic molecules and peptides that dis-
rupt or modulate specific interactions between TMDs could have valuable research and applied
uses. Genetic selection of traptamers will be a powerful tool to elucidate additional rules governing
transmembrane interactions and to identify lead compounds for these approaches.
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Materials and methods
Vectors and cloning
The HA-tagged hEPOR and HA-tagged mEPOR genes (originally obtained from S. Constantinescu,
Ludwig Institute) were excised from the pBABE-puro retroviral vector and subcloned into pMSCV-
neo (Clontech, Mountain View, CA) using EcoRI and HpaI restriction sites. An MluI restriction site
was introduced into the mEPOR and hEPOR genes as a silent mutation at position 642 (ACG CGC
to ACG CGT) by using standard QuickChange Site-Directed Mutagenesis protocol and Pfu Turbo
polymerase (Agilent Technologies, Santa Clara, CA). The mhm chimeric EPOR and mEPOR mutants
containing point mutations in the mEPOR TMD were constructed by cloning double-stranded DNA
gBlock Gene Fragments (Integrated DNA Technologies, Redwood City, CA) containing the wild-
type hEPOR TMD or the desired mutation(s) in the mEPOR TMD into mEPOR gene using MluI and
ApaI restriction sites (corresponding to amino acids Arg214 to Pro328 of the mEPOR protein). The
hmh chimeric EPOR and the L238S mutant of the hEPOR were constructed by first cloning double-
stranded DNA gBlock Gene Fragments containing the wild-type mEPOR TMD or the L238S mutation
in the hEPOR TMD into the hEPOR gene in pBABE-puro vector using MluI and BglII restriction sites
(corresponding to amino acids Arg215 to Lys256 of the hEPOR protein), and then sub-cloned into
pMSCV-neo using EcoRI and HpaI restriction sites. The D259 hEPOR truncation mutant was con-
structed in pMSCV-neo by using Phusion High Fidelity DNA polymerase(ThermoFisher Scientific,
Waltham, MA) to delete the codons between codon 259 and the stop codon. The F8 mutant of the
hEPOR was constructed by replacing sequences encoding the cytoplasmic segment of the HA-
hEPOR gene with a DNA gBlock Gene Fragment containing eight tyrosine-to-phenylalanine muta-
tions. Mutants of traptamer LH5 were constructed by cloning double-stranded DNA gBlock Gene
Fragments containing the desired sequence into pMSCV-puro using XhoI and EcoRI restriction sites.
Cells, retrovirus infections, and activity testing
Retrovirus stocks were prepared in human embryonic kidney (HEK) 293 T cells, which were obtained
from the American Type Culture Collection (CRL3216, Manassas, VA) and maintained in DMEM-10
medium: Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum
(FBS) (Gemini Bioproducts, West Sacramento, CA), 4 mM L-glutamine, 20 mM HEPES (pH 7.3), and
1X penicillin/streptomycin (P-S). All biological experiments were performed in murine interleukin-3
(IL-3)-dependent BaF3 cells, which were obtained from Alan D’Andrea (Dana-Farber Cancer Institute)
and maintained in RPMI-10 media: RPMI-1640 supplemented with 10% heat-inactivated FBS, 5%
WEHI-3B cell-conditioned medium (as the source of IL-3), 4 mM L-glutamine, 0.06 mM b-mercaptoe-
thanol, and 1X P-S. We used several phenotypic and biochemical markers to authenticate our cell
lines. BaF3 cells have a distinctive morphology, and unlike the other cells used in the laboratory they
grow in suspension. The presence or absence of expression of EPOR and traptamers in the appropri-
ate cell line was confirmed by western blotting (e.g. see Figure 3D and Figure 3—figure supple-
ment 1). We confirmed that all cells were IL-3 dependent unless they expressed the EPOR and an
active traptamer. EPOR integrity was confirmed by showing that cells expressing EPOR could prolif-
erate in the presence of EPO, whereas EPO did not support proliferation in cells lacking EPOR
expression. These points are illustrated, for example, in Figure 2A. All cells were shown to be myco-
plasma-free.
To produce retrovirus stocks, 293 T cells were transfected by mixing 2 mg pantropic pVSV-G
(Clontech), 3 mg pCL-Eco (Imgenex, Littleton, CO), 5 mg of the retroviral expression plasmid of inter-
est with 250 ml of 2x HEBS. 250 ml of 0.25 M calcium chloride was then bubbled into each mixture.
The mixture (~500 ml) was incubated for 20 min at room temperature and then added drop-wise into
2.0  106 293 T cells plated in 100 mm tissue culture dishes in DMEM-10. After the cells were incu-
bated with the transfection mixture for 6–8 hr at 37˚C, the medium was replaced with 5 mL fresh
DMEM-10 medium. The cells were incubated for another 48 hr at 37˚C, then the viral supernatant
was harvested, filtered through a 0.45 mm filter (Millipore, Danvers, MA), and either used immedi-
ately or stored at  80˚C.
For IL-3 independence assays, 2  105 BaF3 cells expressing the appropriate genes were washed
in PBS three times to remove IL-3. Cell pellets were resuspended in 10 mL RPMI-10 IL-3-free
medium, in which WEHI-3B cell-conditioned medium was not included. Viable cells were counted six
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days after IL-3 removal. All IL-3 tests were performed in three independent biological replicates (i.e.
independent infections to express traptamers followed by cell counts after IL-3 removal). All
reported experiments included positive and negative controls that performed as expected, and no
outliers in these experiments were excluded. All graphs show average values for IL-3 tests ± SEM.
Statistical significance of differences between control and experimental samples was evaluated by
two-tailed Student’s t-tests with unequal variance, performed using T.TEST function in Microsoft
Excel (2013). Significance cut-off for differences in cell numbers was established by p value < 0.05.
BaF3 cells expressing HA-tagged hEPOR, HA-tagged mEPOR, and all EPOR mutants were gener-
ated by infecting BaF3 cells with pMSCV-neo vector containing the desired EPOR gene. 5  105
BaF3 cells were washed with phosphate buffered saline (PBS) and then re-suspended in 500 ml
RPMI-10 medium with 4 mg/mL polybrene. 500 ml retroviral supernatant or 500 ml DMEM-10 for
mock-infection was added to re-suspended cells and incubated for 6 hr at 37˚C. After incubation, 9
ml RPMI-10 was added and the BaF3 cells were incubated overnight at 37˚C prior to selection in 1
mg/mL G418 or 1 mg/mL puromycin, as appropriate.
BaF3 cells co-expressing HA-tagged full-length hEPOR and truncated hEPOR (D259) were gener-
ated by infecting BaF3 cells as above with pMSCV-neo expressing D259, followed by selection with
1 mg/mL G418 for five days. The selected cells were then infected with pMSCV-neo containing the
full-length hEPOR gene, followed by selection with 0.25 mg/mL G418 plus 0.6 U/ml human recombi-
nant EPO for three days in the absence of IL-3. Immunoblotting with anti-HA antibody confirmed the
expression of full-length and truncated EPORs. Traptamers cloned in MSCV-puro were introduced
into these cells by infection followed by puromycin selection.
Retroviral library construction, Screening, and Recovery
The UDv6 library was previously described (Heim et al., 2015). The library, containing sequences
encoding an estimated five million different traptamers (based on the number of bacterial colonies
pooled), was transfected into 293 T cells to generate a retrovirus stock. For the screening, six million
BaF3/hEPOR cells were divided equally into six 25 cm2 flasks with 1 ml RPMI-10 media in each flask
and then infected with 1 ml of 20X concentrated retroviruses containing the UDv6 library at multi-
plicity of infection of ~1. Polybrene was added to a final concentration of 4 mg/mL.
Cells were incubated at 37˚C for four hours before 8 ml fresh RPMI-10 media was added to each
flask. 24 hr post-infection, 1 mg/mL puromycin was added to each flask. The puromycin selection
continued for 3–4 days until all cells from mock infection were dead. 5  105 cells were then col-
lected from each pool, washed twice in PBS, and resuspended in 10 mL medium containing 1/20 of
the standard IL-3 concentration (reduced IL-3 medium). After 14 days, live cells were collected from
each pool. Genomic DNA (gDNA) was isolated using DNeasy Blood and Tissue Kit (
Qiagen, The Netherlands). Library inserts were recovered from gDNA by using PCR with short pri-
mers specific to the library (as described in [Heim et al., 2015]). PCR products were then purified,
digested with EcoRI and XhoI, and cloned into pMSCV-puro vector for the second round of
screening.
DNA from the first round of screening was combined and transfected into 293 T cells to generate
a secondary retrovirus stock. The second round screening was similar to the first round except that
cells were resuspended in 10 mL medium without IL-3, rather than in reduced IL-3 medium. Gene
fragments were recovered from the gDNA of cells proliferating in the absence of IL-3, cloned into
pMSCV-puro vector, and sequenced.
Immunoprecipitation and immunoblotting
Prior to collection, BaF3 cells were starved in RPMI-10 IL-3-free media for 3 hr at 37˚C and, in some
cases, acutely stimulated with 5 U/mL EPO for 10 min at 37˚C. Cells were then washed twice with
ice-cold PBS containing 1 mM phenylmethylsulfonyl fluoride (PMSF). For phosphotyrosine and phos-
pho-protein blots, 1X HALT Protease and Phosphatase Inhibitor Cocktail (ThermoFIsher Scientific)
and 500 mM hydrogen peroxide-activated sodium metavanadate were also added. Cells were lysed
in FLAG-lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton-100) supplemented
with protease and phosphatase inhibitors as above. All lysates were incubated on ice for 20 min, fol-
lowed by centrifugation at 14,000 rpm for 30 min at 4˚C. The total protein concentration of the
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supernatants was determined using a bicinchoninic acid (BCA) protein assay kit (ThermoFisher
Pierce, Waltham, MA).
To immunoprecipitate HA-tagged EPORs for phosphotyrosine blotting, 2 ml of anti-HA antibody
(clone C29F4, Cell Signaling, Danvers, MA) was added to 0.5 mg of total protein and rotated over-
night at 4˚C. 50 ml Protein A Sepharose bead slurry was added and rotated for two hours at 4˚C. To
immunoprecipitate full-length hEPORs to assay receptor dimerization, 8 ml of a rabbit anti-EPOR
polyclonal antibody (clone C-20, Santa Cruz Biotechnology, Dallas TX) was added to 0.5 mg of total
protein and rotated overnight at 4˚C. 50 ml Protein A Sepharose bead slurry was then added and
rotated for two hours at 4˚C. To immunoprecipitate FLAG-tagged traptamers, 50 ml of anti-FLAG
M2 matrix gel (Sigma-Aldrich, Ronkonkoma, NY) was added to 0.5 mg of total protein and rotated
overnight at 4˚C.
Immunoprecipitated samples were washed four times with 1 mL NET-N buffer (100 mM NaCl, 0.1
mM EDTA, 20 mM Tris-HCl pH 8.0, 0.1% Nonidet P-40) supplemented with protease and phospha-
tase inhibitors as above, pelleted and re-suspended in 2x Laemmli sample buffer (2x SB) with 200
mM dithiothreitol (DTT) and 5% b-mercaptoethanol (b-ME). Precipitated proteins and whole cell
lysates were heated at 95˚C for 5 min and then resolved by SDS-PAGE on either 10%, 15% or 20%
polyacrylamide gels according to the size of the protein. The resolving gel was then transferred by
electrophoresis to a 0.2 mm nitrocellulose membrane. SDS was added to the transfer buffer in order
to detect phosphorylated proteins.
Membranes were blocked with gentle agitation for one hour at room temperature in 5% nonfat
dry milk/TBST (1X Tris buffered saline plus 0.1% Tween-20). To detect phosphorylated EPOR, a
mouse anti-phosphotyrosine monoclonal antibody PY100 (Cell Signaling) was used at a 1:1000 dilu-
tion; to detect phosphorylated JAK2, a rabbit anti-phospho-JAK2 monoclonal antibody (Tyr1008)
(clone D4A8, Cell Signaling) was used at 1:1000 dilution; to detect total JAK2, a rabbit anti-JAK2
monoclonal antibody (clone D2E12, Cell Signaling) was used at 1:1000 dilution; to detect HA-tagged
EPORs, an HRP-conjugated mouse anti-HA (clone 6E2, Cell Signaling) was used at 1:1000 dilution.
Membranes were incubated overnight with gentle agitation in primary antibody at 4˚C, washed five
times in TBST, and then incubated with gentle agitation for one hour at room temperature in donkey
anti-mouse or donkey anti-rabbit HRP (Jackson Immunoresearch, West Grove, PA), as appropriate,
at a 1:10,000 dilution. To reprobe phospho-JAK2 and PY100 blots, membranes were stripped in
Restore Western Stripping Buffer (ThermoFisher Scientific) for 8 min at room temperature with gen-
tle agitation, washed five times in TBST, blocked in 5% milk/TBST for one hour at room temperature,
and incubated overnight at 4˚C with anti-JAK2 or anti-HA-HRP antibody, respectively, as described
above. Membranes were incubated with Super Signal West Pico or Femto Chemiluminescent Sub-
strates (Pierce ThermoFisher) to detect protein bands.
To assess EPOR oligomerization, we first used immunoblotting with anti-HA to document that
full-length-hEPOR and D259 were expressed in the appropriate cell lines (Figure 3D, bottom panel).
To confirm the specificity of the C-20 antibody, detergent lysates of BaF3/hEPOR, BaF3/D259 and
BaF3/D259-hEPOR cells, all lacking traptamer expression, were immunoprecipitated by C-20 anti-
body, subjected to gel electrophoresis and immunoblotted with anti-HA. Full-length hEPOR was
immunoprecipitated whether or not the cells co-expressed D259 (lanes 1 and 3 of Figure 3D, top
panel), but a minimal amount of D259 was precipitated by C-20, even when hEPOR was co-
expressed (lanes 2 and 3 of Figure 3D, top panel).
Expression and purification of peptides for NMR studies
DNA sequences encoding the TMD segment of human EPOR (residues Leu217 to Gly277
[hEPOR217-277], of which residues 226 to 247 constitute the TMD) or human GHR (residues 238 to
274, of which the residues 247 to 270 constitute the TMD) were synthesized and cloned into the
pGEX-4T1 vector carrying an N-terminal GST protein and a thrombin cleavage site. FLAG-tagged
LH5 traptamer and its mutants LH5-L9I and LH5-I10L were cloned into the same vector with an addi-
tional TEV cleavage site in the order: GST-thrombin cleavage site-TEV cleavage site- FLAG-tag-trans-
membrane sequence. Plasmids were transformed into E. coli, and the cells grown in either unlabeled
LB medium (for traptamer constructs) or in 15N-labelled M9 medium (for receptor TMD constructs)
supplemented with 100 mg ampicillin to a cell density of 0.5 at OD600. Protein expression was
induced with 1 mM isopropyl b-D-1-thiogalactopyranoside (IPTG), and cells were harvested 4 hr after
induction. All four fusion-proteins were expressed into inclusion bodies, which were harvested by
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three cycles of sonication and centrifugation. The inclusion bodies were washed in 50 mM Tris-HCl,
pH 7.4 and solubilized in 1.5% (w/v) N-lauroylsarcosine and 100 mM DTT in 50 mM Tris-HCl, pH 7.4.
After gentle agitation overnight the insoluble material was removed by centrifugation at 12000 x g
and the solubilized proteins dialyzed two times against four L of 0.5% (w/v) N-lauroylsarcosine in 50
mM Tris-HCl, pH 7.4. GST was cleaved off with thrombin (3 units/mL) and the released peptides puri-
fied utilizing a chloroform/methanol extraction as described (Bugge et al., 2015), dried under a con-
tinuous flow of N2 gas and stored at  20˚C until use.
NMR spectroscopy and titrations
All NMR spectra were recorded at 37˚C on a 750 MHz AVANCE Bruker spectrometer equipped with
a cold probe. Spectra for backbone assignments of hEPOR217-277 (HNCO, HNCAHC, HNCA,
HNCACB, CBCACONH, HSQC) were recorded on 1 mM hEPOR217-277 solubilized in 40 mM dihexa-
noylphosphatidylcholine (DHPC), 10% (v/v) D2O, 2 mM tris (2-carboxyethyl)phosphine (TCEP), 1 mM
4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS), 0.05% (v/v) NaN3, 50 mM NaCl, and 20 mM
Na2HPO4/NaH2PO4, pH 7.4. Proton chemical shifts were referenced internally to DSS at 0.00 ppm,
heteronuclei by their relative gyromagnetic ratios. Monomer-dimer equilibrium-induced chemical
shift changes of hEPOR217-277 at different DHPC concentrations were derived from comparing HSQC
spectra of 0.5 mM hEPOR217-277 in 25 mM DHPC giving a ratio of 1:30 of EPOR:DHPC to spectra of
0.5 mM hEPOR217-277 in 40 mM DHPC giving a ratio of 1:60 of EPOR:DHPC. To achieve different
ratios of traptamer to hEPOR217-277 and DHPC, sample conditions were adjusted to 0.5 mM
hEPOR217-277 in 25 mM DHPC for (0:2):30 [molar ratios of (traptamer:hEPOR):DHPC], 0.25 mM trap-
tamer and 0.5 mM 15N hEPOR217-277 in 32.5 mM DHPC at (1:2):30 ratios, and 0.5 mM traptamer and
0.5 mM 15N hEPOR217-277 in 40 mM DHPC at (2:2):30 ratios. HSQC NMR spectra of hGHR238-274
without and with LH5-L9I (ratio 4:2) were recorded on 0.25 mM 15N hGHR238-274 in 25 mM DHPC
and on 0.25 mM 15N hGHR238-274 and 0.5 mM traptamer in 55 mM DHPC, respectively. All NMR
samples contained 10% (v/v) D2O, 2 mM TCEP, 1 mM DSS, 0.05% (v/v) NaN3, 50 mM NaCl, and 20
mM Na2HPO4/NaH2PO4, pH 7.4. Chemical shift changes were extracted from
1H,15N-HSQC spectra







In all replicate NMR experiments on different batches of peptides, the chemical shift differences
induced by the traptamers did not vary more than a maximum of 0.04 ppm between data sets.
To achieve high ratios of LH5 to hEPOR217-277 in the titrations, sample conditions were adjusted
to 0.33 mM hEPOR217-277 in 30 mM DHPC for (0:1):60 [molar ratios of (LH5:hEPOR):DHPC], 0.33 mM
LH5 and 0.33 mM 15N hEPOR217-277 in 50 mM DHPC at (1:1):60 ratios, 0.66 mM LH5 and 0.33 mM
15N hEPOR217-277 in 70 mM DHPC at (2:1):60 ratios, and 1.32 mM LH5 and 0.33 mM
15N hEPOR217-
277 in 110 mM DHPC at (4:1):60 ratios. Finally,
1H,13C-HSQC spectra of 13C,15N-hEPOR217-277 were
recorded on 0.5 mM 13C,15N hEPOR217-277 prepared in 25 mM DHPC to achieve molar ratios of
(LH5:hEPOR):DHPC of (0:1):30, and 0.5 mM LH5 and 0.5 mM 13C,15N hEPOR217-277 in 40 mM DHPC
for ratios of (1:1):30.
Structural modeling
Molecular dynamics simulations were run in CHARMM 38b2 (Brooks et al., 2009) using the IMM1
implicit membrane solvation model (Masunov and Lazaridis, 2003). Simulations of EPOR TMD
dimers (hEPOR: LILTLSLILVVILVLLTVALL; mEPOR: LILTLSLILVLISLLLTVLALL) were initialized as ideal
coiled-coils in the VI register, inserted normal to the membrane. Ten 100-ns simulations, with differ-
ent random seeds, were then run from this starting conformation, with trajectory snapshots saved
every 10 ps. To maximize productive sampling of dimeric states, a gentle harmonic restraint was
applied to the distance between helical centroids with a force constant of 0.01 kcal/mol/A˚2 and an
equilibrium distance of 10 A˚. No symmetry restraints were applied in simulations. To prevent arti-
facts at helical termini associated with the lack of the full-length protein context, backbone i-i +4
hydrogen bonding geometries were restrained for one residue at either terminus of each helix. The
restraint was applied to the distance between corresponding backbone N and O atoms with a force
constant of 1 kcal/mol/A˚2 and the equilibrium distance of 2.87 A˚2. Analysis of simulation trajectories
revealed rapid sampling of helical phases with frequent switches between states (in fact, the initial VI
state was rarely visited). The first 10 ns of each trajectory were treated as equilibration and discarded
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in all subsequent analysis. Starting conformations for simulating EPOR TMD dimers in the presence
of traptamers were generated by extracting random EPOR TMD snapshots from the above trajecto-
ries and adding one, two, or four traptamer chains as ideal helices inserted anti-parallel to the EPOR
TMD dimer. Traptamer chains were added with random displacements in the plane of the mem-
brane within a radius of 20 A˚ from the EPOR TMD centroid. For each traptamer/stoichiometry/EPOR
type, 100 such random starting points were generated and each used to initialize a 10-ns simulation
with trajectory snapshots saved every 10 ps. To ensure proper equilibration of the larger traptamer/
EPOR systems, the first 5 ns of each of these simulations were discarded in all analyses. The same
restraints at helical termini as described above were applied to all traptamer chains. In addition, to
prevent traptamers from diffusing away (and resulting in unproductive sampling), a flat-bottom
semi-harmonic potential was applied to keep each traptamer within 20 A˚ of an EPOR TM helix. This
constraint did not contribute energy if the traptamer centroid was within 20 A˚ of an EPOR helix cen-
troid, while outside of this radius the restraint energy increased harmonically (applied to the distance
by which the 20 A˚ limit was exceeded) with a force constant of 1 kcal/mol/A˚2. In the 2:2 and 4:2
topologies, half of the traptamer chains were restrained with respect to one EPOR helix and the
other half with respect to the other helix.
To produce helical phase distributions, EPOR TM dimer structures from 10,000 randomly chosen
trajectory snapshots for each simulation type were subjected to coiled-coil parameter analysis using
the CCCP program (Grigoryan and Degrado, 2011). CCCP finds an ideal coiled-coil structure that
best fits to any given helical bundle. Snapshots that fit with root mean square deviation (RMSD) >0.8
A˚ were ignored as not representing conformations sufficiently close to a coiled-coil to warrant clear
interpretation of resulting parameters (~7,000–8,000 snapshots per simulation type survived this fil-
ter). Parameter values from remaining snapshots were used to construct the plots in Figure 7A.
To study the rate at which the EPOR dimer may symmetrize, we analyzed all 100 independent
implicit-solvent trajectories run for each EPOR/traptamer combination. To limit the effect of the
starting conformation, the first 5 ns was discarded as equilibration, with the remainder used to study
the extent to which the EPOR dimer would be expected to average out to a symmetric structure
over time (i.e., an aggregate of 500 ns were analyzed). Because averaging the structure itself does
not yield geometrically realistic conformations, we instead used a distance matrix-based measure of
symmetry. We computed the distance matrix Mi corresponding to the EPOR part of each simulation
snapshot i(defined as the matrix of distances between all pairs of atoms), and further computed run-
ning averages of this matrix Mn over progressively longer time windows of nsnapshots, starting from
the initial structure (i.e., the mid-point of the original simulation). Next, the degree of symmetry of











, where N is the total number of atoms in the EPOR
dimer, and i
0
is the pseudo-symmetry equivalent counterpart of atom i (i.e., if i belongs to the first
chain of the EPOR dimer, then i
0
is the equivalent atom on the second chain; and vice versa).
All-atom molecular dynamics simulations
The initial atomic co-ordinates for the complexes of the mEPOR and hEPOR TMDs and LH5 were
obtained from representative 2:2 centroid models from the implicit-membrane simulations. Com-
plexes with LH5-L9I and LH5-I10L mutant traptamers were generated by starting with the correspond-
ing LH5 complex and performing the necessary amino-acid substitution using the Rosetta Design
modelling platform (Huang et al., 2011). These models were used as a starting point for all-atom sim-
ulations after adding short juxtamembrane domains to each end of the receptor TMDs. The final
sequences of the EPOR segments used for modeling were as follows, with the TMDs underlined:
hEPOR MSEPASLLTASDLDPLILTLSLILVVILVLLTVALLSHRRTLQQKWIP
mEPOR MSEPASLLTASDLDPLILTLSLILVLISLLLTVALLSHRRTLQQKWIP
These receptor-traptamer complexes were embedded in 1-palmitoyl-2-oleoyl-sn-glycero-3-phos-
phocholine (POPC) bilayers containing 128 lipids per bilayer leaflet using CHARMM-GUI (Jo et al.,
2008). The system was inserted in the center of the membrane perpendicular to the lipid bilayer
plane. The system was solvated using TIP3P water molecules, with Na+ and Cl  ions included to
maintain neutral charge at physiological salt concentration of 0.154 M.
The all-atom MD simulations were carried out with the Gromacs 2016.1 platform using in-house
computing and the Grace high performance computers at Yale University. The AMBER99SB-ILDN-
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GORD_SLipids force field (Lindorff-Larsen et al., 2010) force-field was used after adding the parame-
ters for POPC molecules as established by SLIPIDS (Ja¨mbeck and Lyubartsev, 2012). Energy minimi-
zation was carried out in Gromacs with double precision to permit the system to stabilize. Following
the minimization, an NVT equilibration was undertaken by applying a restraint on the lipids to allow
the water molecules to re-orient around the lipid headgroups and exposed parts of the protein. Next,
NPT equilibration was then carried out in two steps using the Nose´-Hoover thermostat (Nose´, 1984)
and Parinello-Rahman (Parrinello and Rahman, 1981) semi-isotropic coupling with a time constant of
2 fs and a temperature of 293˚K. Long-range interactions were treated with the particle-mesh Ewald
method (Darden et al., 1993) (interpolation order of 4 with a grid spacing of 0.12 nm). Initially the pro-
tein was kept under restraint and the bilayer was allowed to equilibrate around the protein for 5 ns, fol-
lowing which a restraint on the bilayer was applied and the protein was allowed to equilibrate for 2 ns.
The pressure progression and lateral area of the membrane was checked after the NPT equilibration
to ensure system stability. The above protocol was followed for each of the prepared system, and
these were set for a production MD run of 50 ns without any restraint on the water molecules, ions,
protein or the bilayer. The analysis of the MD trajectories was also carried out with Gromacs 2016.1
and the data were plotted using MATLAB (The MathWorks I, 2000).
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